2m 2m 2m 2m 2m 2m 2m
- $135.9MMarket Cap
- -16.39%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
JOURNEY MEDICAL (DERM)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 58
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Pomerantz LLP is investigating Journey Medical Corporation for potential securities fraud following the company's March 25, 2026 earnings report. Management disclosed that prescription demand for Emrosi exceeded reported revenue due to reimbursement timing and co-pay assistance program usage, with some scripts not being reimbursed. The stock fell 30.01% to $4.78 per share on March 26, 2026, prompting the class action investigation.
04/28/2026, 4:57 PM • GlobeNewswire
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica
The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.
02/10/2026, 5:55 AM • GlobeNewswire
Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.
08/20/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Key Executives
- Claude Maraoui
- Ramsey Alloush
- Joseph Benesch
- Lindsay Allan Rosenwald
- Robert Nevin
Current Ownership Distribution
- Mutual Funds520.4M (82.56%)
- Institutions69.4M (11.01%)
- Insiders40.5M (6.43%)
- Other0 (0.00%)